On July 5, 2024, the academic exchange meeting entitled "Discussion of Frontier Diagnosis and Treatment Directions in Lung Cancer Surgery" co-hosted by Department of Thoracic Surgery, along with Department of Oncology and Department of Radiation Oncology of the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU), was successfully held. Professor Tetsuya Mitsudomi from Kindai University School of Medicine in Japan was invited to conduct academic exchanges on the hot issues and the latest progress in the field of comprehensive treatment of lung cancer. The exchange meeting was chaired by Zhang Guangjian, Director of Department of Thoracic Surgery.

Feng Guanglin, Deputy Secretary of FAH, delivered a welcome speech, hoping that Professor Tetsuya Mitsudomi, as a visiting professor in FAH, would bring new energy and motivation to disciplinary development and progress by sharing his knowledge and experience. Yao Yu, Director of Department of Oncology delivered an online speech, hoping that bilateral sides can strengthen mutual cooperation in the field of diagnosis and treatment of lung cancer. Subsequently, Deputy Secretary Feng Guanglin presented the letter of appointment as a visiting professor to Professor Tetsuya Mitsudomi.

Deputy Chief Physician Meng Du from Department of Radiation Oncology introduced MDT discussion and diagnosis system in FAH, and showcased the mechanism and advantages of MDT consultation. PhD Gao Shan from Department of Thoracic Surgery reported a case of transformation treatment for lung cancer by MDT consultation, and MDT team members shared their treatment experience. Professor Tetsuya Mitsudomi highly recognized FAH’s achievements of MDT in lung cancer. Based on the effectiveness of current treatment of this case, he suggested that similar patients should be treated in FAH under the framework of clinical research in the future, aiming to accumulate more convincing evidence for clinical diagnosis and treatment rather than a single case report. At the same time, Professor Tetsuya Mitsudomi suggested that sequential targeted maintenance therapy with synchronous radiochemotherapy could be considered according to the results of LAURA's research. After disease progression, Amivantamab+Lazertinib double targeted therapy may be adopted according to the results of MARIPOSA study.

After the discussion, Professor Tetsuya Mitsudomi visited the wards of Department of Thoracic Surgery, and then visited the linear accelerator of Department of Radiation Oncology and domestically-manufactured TACHI linear accelerator. Both two sides expectated to further promote bilateral exchanges through this academic activity.